Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency

@inproceedings{Fintini2009ProfileOM,
  title={Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency},
  author={Danilo Fintini and Claudia Brufani and Marco Cappa},
  booktitle={Therapeutics and clinical risk management},
  year={2009}
}
Growth hormone insensitivity syndrome (GHI) or insulin-like growth factor-1 (IGF-1) deficiency (IGFD) is characterized by deficit of IGF-1 production due to alteration of response of growth hormone (GH) receptor to GH. This syndrome is due to mutation of GH receptor or IGF-1 gene and patients affected showed no response to GH therapy. The only treatment is recombinant IGF-1 (mecasermin), which has been available since 1986, but approved in the United States by the US Food and Drug… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

The role of recombinant human insulin - like growth factor - I in treating children with short stature

  • R Keret, A Pertzelan, A Zeharia, Z Zadik, Z Laron
  • J Clin Endocrinol Metab
  • 2008

Similar Papers

Loading similar papers…